Eicosanoids and Diabetic Hypertension
Hypertension is more common in juvenile onset diabetes than in the normal population and is considered to be a major risk factor in this group of patients (Christlieb et al. 1981). More than 2.5 million Americans suffer from diabetes associated with hypertension (Working Group on Hypertension in Diabetes 1987). The development of the vascular complications of diabetes, namely diabetic macro- and microangiopathy and the prothrombotic stage, eventually combined with diabetic hypertension, might be facilitated by a more general disturbance in the defence mechanisms of the body, being related to insulin deficiency. This involves alterations in eicosanoid production that are not only important for control of insulin secretion (Rösen and Hohlfeld 1985; Robertson 1986) but also for the vascular and thrombotic complications of the disease. This paper reviews the present evidence for a contribution of disturbed eicosanoid production to the vascular complications in diabetes mellitus with particular emphasis on hypertension.
KeywordsCholesterol Acid Value Neuropathy Prostaglandin Norepinephrine
Unable to display preview. Download preview PDF.
- Bresser H-J, Rösen P, Schrör K (1987) Insulin treatment normalizes the arachidonie acid induced prostacyclin release from the platelet-perfused diabetic rat heart. Evidence for major changes in 15- HETE production. In: Sinzinger H, Sehrör K (eds) Prostaglandins in Clinical Research Alan R. Liss, Inc. New York, p 143–148Google Scholar
- Broderick R, Tulenko T (1983) Cholesterol increases noradrenalin ( NE) sensitivity in perfused rabbit femoral arteries. Fed Proc 42: 1387Google Scholar
- Guicheney P, Baudoin-Legros M, Meyer P (1987) Study of in vivo platelet activation in uncomplicated essential hypertension. Thromb Res 40: 615–621Google Scholar
- Johnson M, Harrison HE, Raftery AT, Eldor JB (1979) Vascular prostacyclin may be reduced in diabetes in man. Lancet i: 325–326Google Scholar
- Karpen CW, Cataland S, O’Dorisio CM, Panganamala RV (1985) Production of 12-hydroxyeicosatetraenoic acid and vitamin E status in platelets from type I human diabetic subjects. Diabetes 34: 526–531Google Scholar
- McNamara DB, Donath GR, Kadowitz PJ, Hyman AL, Rush DS, Kerstein MD (1986) Prostacyclin synthetase activity in human diabetic and nondiabetic vascular tissue. J Vase Surg 4: 63–67Google Scholar
- Mourits:Andersen T, Jensen R, Dyerberg J (1986) Plasma prostaglandins: 6-keto-PGFla, TXB2 and PGE2 in juvenile-onset diabetes determined by high-pressure liquid chromatography and radioimmunoassay. Prostaglandins Leukotrienes Med 22: 335–348Google Scholar
- Müller SM, Müller TM, Ertel PJ (1982) Sympathetic and vascular dysfunction in early experimental juvenile diabetes mellitus. Am J Physiol 243: H139–H144Google Scholar
- O’Malley BC, Timperly WR, Ward JD, Porter NR (1975) Platelet abnormalities in diabetic peripheral neuropathy. Lancet ii: 1274–1276Google Scholar
- Pottathil R, Huang SW, Chandrabose KA (1985) Essential fatty acids in diabetes and systemic lupuserythematosus (SLE) patients. Biochem Biophys Res Commun 128: 803-808 Quilley J, McGiff JC (1986) Influence of insulin on urinary eicosanoid excretion in rats with experi¬mental diabetes mellitus. J. Pharmacol Exp Ther 238: 606–611Google Scholar
- Setty BN, Stuart MJ (1986) 15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease. J Clin Invest 77: 202–211Google Scholar